Novo Nordisk A/S
- Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient - The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways
- Shares in Wegovy-maker Novo Nordisk pop 6% after GLP-1 pill approval - The FDA on Monday approved the first-ever GLP-1 pill from the Danish pharmaceutical giant.
- FDA approves first GLP-1 pill for obesity from Novo Nordisk - Health and ScienceFDA approves first GLP-1 pill for obesity from Novo NordiskPublished Mon, Dec 22 20256:06 PM ESTUpdated 1 Min AgoAnnika Kim Constantino@annika
- Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
- Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple - Dealmakers expected a flood of M&A to take place in 2025 following the election of President Trump. The number of transactions didn't live up to the hype.
- This is how exposed European Big Pharma is to the U.S. - U.S. pricing has been the bigegts issue of the year for drugmakers heavily exposed to the U.S. market.
- Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial - The drugmaker is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill.
- Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site - The announcement comes weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access.